NTRB icon

Nutriband

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
Newsfile Corp
18 days ago
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
Orlando, Florida--(Newsfile Corp. - November 24, 2025) - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman and Co-Founder, Serguei Melnik will present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Wednesday, December 3rd at 9.30 AM Eastern Standard Time.
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
Neutral
GlobeNewsWire
1 month ago
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Neutral
GlobeNewsWire
1 month ago
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Neutral
GlobeNewsWire
2 months ago
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Neutral
GlobeNewsWire
2 months ago
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing  opioids and stimulants with a potential for abuse. Nutriband's AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Neutral
GlobeNewsWire
2 months ago
Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference
ORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman Serguei Melnik will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Wednesday, October 8 at 15:00 Eastern Standard Time.
Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference
Neutral
GlobeNewsWire
2 months ago
Nutriband Inc. to Present at the MicroCap Rodeo Conference
ORLANDO, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (The Company) (Nasdaq:NTRB) (Nasdaq: NTRBW), announces it will participate in the MicroCap Rodeo Conference, to be held Thursday, June 25, 2025, in New York City.
Nutriband Inc. to Present at the MicroCap Rodeo Conference
Neutral
GlobeNewsWire
3 months ago
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025.
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
Negative
Zacks Investment Research
3 months ago
Nutriband Inc. (NTRB) Reports Q2 Loss, Lags Revenue Estimates
Nutriband Inc. (NTRB) came out with a quarterly loss of $2.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago.
Nutriband Inc. (NTRB) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of $6.43 for proceeds to the company of $5,306,000.
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000